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Abstract The Japanese surveillance committee con-
ducted the ﬁrst nationwide surveillance of antimicrobial
susceptibility patterns of uropathogens responsible for
female acute uncomplicated cystitis at 43 hospitals
throughout Japan from April 2009 to November 2010. In
this study, the causative bacteria (Escherichia coli and
Staphylococcus saprophyticus) and their susceptibility to
various antimicrobial agents were investigated by isolation
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and culturing of bacteria from urine samples. In total, 387
strains were isolated from 461 patients, including E. coli
(n = 301, 77.8 %), S. saprophyticus (n = 20, 5.2 %),
Klebsiella pneumoniae (n = 13, 3.4 %), and Enterococcus
faecalis (n = 11, 2.8 %). S. saprophyticus was signiﬁ-
cantly more common in premenopausal women
(P = 0.00095). The minimum inhibitory concentrations of
19 antibacterial agents used for these strains were deter-
mined according to the Clinical and Laboratory Standards
Institute manual. At least 87 % of E. coli isolates showed
susceptibility to ﬂuoroquinolones and cephalosporins, and
100 % of S. saprophyticus isolates showed susceptibility to
ﬂuoroquinolones and aminoglycosides. The proportions of
ﬂuoroquinolone-resistant E. coli strains and extended-
spectrum b-lactamase (ESBL)-producing E. coli strains
were 13.3 % and 4.7 %, respectively. It is important to
conﬁrm the susceptibility of causative bacteria for optimal
antimicrobial therapy, and empiric antimicrobial agents
should be selected by considering patient characteristics
and other factors. However, the number of isolates of
ﬂuoroquinolone-resistant or ESBL-producing strains in
gram-negative bacilli may be increasing in patients with
urinary tract infections (UTIs) in Japan. Therefore, these
data present important information for the proper treatment
of UTIs and will serve as a useful reference for future
surveillance studies.
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Introduction
Urinary tract infections (UTIs) are among the most com-
mon diseases caused by bacteria in adults and should be
treated with effective antimicrobial chemotherapy. How-
ever, the treatment of UTIs is becoming more difﬁcult
because of increasing bacterial resistance to antimicrobial
agents.
Many surveys on antimicrobial susceptibility of the
organisms have been performed in Japan and the results are
widely used as a guide for selecting appropriate antibac-
terial therapy [1–4]. To investigate comprehensively the
antimicrobial susceptibility and resistance of bacterial
urinary pathogens, the Japanese Society of Chemotherapy
(JSC) established a nationwide surveillance network in
2006. The ﬁrst survey was conducted during the period
from January to December in 2008, and we reported the
trend of antimicrobial susceptibilities of bacterial species
isolated from patients with UTIs [4]. To use antimicrobials
appropriately, information on the antibiotic susceptibility
of the pathogens isolated from UTIs is of particular value.
Therefore, the distribution of causative bacteria and their
susceptibility to various antimicrobial agents were inves-
tigated by a survey of urine specimens from patients with
acute uncomplicated cystitis (AUC).
Here we report a study of nationwide surveillance for
AUC conducted by the JSC, the Japanese Associations for
Infectious Diseases (JAID), and the Japanese Society for
Clinical Microbiology (JSCM). The purpose of this study
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was to investigate the antimicrobial susceptibility of the
pathogens isolated from AUC by a nationwide survey, and
to record the data for future comparison with antibiotic-
resistant organisms obtained by periodic surveillance.
Materials and methods
The Japanese surveillance committee
The Japanese surveillance committee, consisting of the
JSC, JAID, and JSCM, conducted the ﬁrst nationwide
surveillance of antimicrobial susceptibility patterns of
uropathogens responsible for female AUC. The study
protocol was prepared by the working group and accepted
by the governing board of the Japanese surveillance com-
mittee. Ethics approval was the responsibility of each
facility. The facilities that did not have an ethical com-
mittee submitted this study to the ethical committee of the
speciﬁc nonproﬁt organization CREC net, Kitakyushu,
Japan, which approved it. The clinicians who participated
in this study explained the purpose of the study to the
patients orally or through written documents and obtained
the written consent of each patient. All data were reported
to the study database with patient information remaining
anonymous and conﬁdential.
Patients
Among the patients with AUC who visited any of the 43
institutions (Table 1) across Japan from April 2009 to
November 2010, those who had symptoms such as mictu-
ritional pain, frequent urination, urgency, or suprapubic
pain, and who met the following inclusion criteria were
enrolled.
Inclusion criteria were set in accordance with the
guidelines for clinical trials on genitourinary tract infec-
tions, version 1 [5]. Patients with AUC were required to be
female, aged 16 years or older, lacking underlying urinary
tract disease and/or factors contributing to the onset,
worsening, or prolongation of urinary tract infection; dia-
betes mellitus, malignancy under treatment, cerebrovas-
cular disease requiring assistance, and corticosteroid or
immunosuppressant therapy. One or more of the following
was also required: pyuria conﬁrmed by a reagent strip; C5
white blood cells (WBCs) per high-power ﬁeld (hpf) on
microscopy of urine sediment, or C10 WBCs/mm3 mea-
sured by ﬂow cytometry or a counting chamber; and bac-
teriuria C103 colony-forming units (cfu)/ml (for midstream
urine, C104 cfu/ml).
Bacteriological examination
Collection of urine samples and bacterial strains
Urine samples were collected from patients with AUC as
midstream urine or via a catheter in accordance with the
guidelines for clinical trials on genitourinary tract
infections, version 1 [5]. They were spread on Slide-
culture U (Eiken Chemical, Tokyo, Japan) by the
investigators and were sent on the same day to a central
bacteriological laboratory (the Research Center for
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Anti-infective Drugs of the Kitasato Institute, Kanagawa,
Japan) for testing.
Bacterial strains received from the medical institutions
were cultured at 37 C for 16–24 h, and isolates were
identiﬁed, counted, and stored at -80 C for future
investigation.
Susceptibility testing and determination of the minimal
inhibitory concentration (MIC)
MICs against two main causative organisms of AUC,
Escherichia coli and Staphylococcus saprophyticus, were
measured by the broth microdilution method according to
the guidelines of the Clinical and Laboratory Standards
Institute (CLSI) set out in standards M7-A7 [6], M100-S17
[7] and M45-A [8] using a cation-adjusted Mueller–Hinton
broth (25 mg/l Ca2? and 12.5 mg/l Mg2?; CA-MH broth).
Bacterial cells were grown overnight, adjusted to approx-
imately 104 cfu/well (105 cfu/ml), and incubated at
35 ± 2 C for 16–20 h.
Quality control
Accuracy of determination of the MIC of antimicrobial
agents was controlled according to the recommendations of
the CLSI, using the following control strains: E. coli
ATCC25922 for E. coli and S. aureus ATCC29213 for
S. saprophyticus. E. coli ATCC35218 was used as a control
strain for the MIC determination of b-lactam antibiotics
combined with b-lactamase inhibitors.
Antibacterial agents
The susceptibilities of E. coli strains were tested for the
following 17 antimicrobial agents: one penicillin,
ampicillin (ABPC; Meiji); one penicillin in combination
with b-lactamase inhibitors, clavulanic acid–amoxicillin
(CVA/AMPC; Glaxo SmithKline); ﬁve oral cephalospo-
rins, cefaclor (CCL; Shionogi), cefpodoxime (CPDX;
Table 1 Cooperative medical institutions in Japan
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Daiichi-Sankyo), cefdinir (CFDN; Astellas Pharma), cef-
ditoren (CDTR; Meiji), and cefcapene (CFPN; Shionogi);
one penem, faropenem(FRPM; Astellas); two aminogly-
cosides, gentamicin (GM; Shionogi) and amikacin (AMK;
Banyu); ﬁve ﬂuoroquinolones, ciproﬂoxacin (CPFX;
BayerYakuhin), levoﬂoxacin (LVFX; Daiichi-Sankyo),
tosuﬂoxacin (TFLX; Toyama), pruliﬂoxacin (PUFX;
Kyorin Pharmaceutical), and sitaﬂoxacin (STFX; Daiichi-
Sankyo); and two others, fosfomycin (FOM; Meiji) and
sulfamethoxazole/trimethoprim (ST; Shionogi).
The susceptibilities of S. saprophyticus strains were
tested for 17 antimicrobial agents in the same manner as
the E. coli testing, as well as two glycopeptides: vanco-
mycin (VCM; Shionogi) and teicoplanin (TEIC; Astellas).
Detection of b-lactamase production
The Cica-beta test (Kanto Chemical, Tokyo, Japan), a
recently developed, rapid method for the detection of
extended-spectrum b-lactamase (ESBL)-producing E. coli,
was used by directly scraping a colony and applying it on
the disk [9, 10]. These tests were conducted according to
the reference manual supplied by the manufacturer.
Investigation of patient characteristics
On the day of urine collection, investigators interviewed
each patient to obtain data on the following characteristics:
age, menopausal status, and method for collection of urine
sample. The patient’s clinical data and the bacterial species
identiﬁed were recorded on a standardized data sheet. The
microbiological data obtained were analyzed according to
the clinical settings and proﬁles of the patients.
Assessment
Assessment of antimicrobial susceptibility
The antimicrobial susceptibility of the pathogens was cate-
gorized into three classes, namely, susceptible, intermediate,
or resistant, according to the MIC breakpoints recommended
by CLSI standards M100-S18 [11], and the susceptibility rate
was deﬁned as thepercentageof susceptible strains. For agents
not described in the CLSI guidelines, breakpoints were set
based on those for similar agents. The breakpoints for LVFX
in the CLSI guidelines are B2 lg/ml (susceptible), 4 lg/ml
(intermediate), andC8 lg/ml (resistant), and those for CPFX
are B1, 2, and C4 lg/ml, respectively. Thus, the corre-
sponding values for TFLX, PUFX, and STFX were likewise
set at B1 lg/ml (susceptible), 2 lg/ml (intermediate), and
C4 lg/ml (resistant). The breakpoints for CPDX in the CLSI
guidelines are B2 lg/ml (susceptible), 4 lg/ml (intermedi-
ate), andC8 lg/ml (resistant), and those for CFDN areB1, 2,
and C4 lg/ml, respectively. Thus, the corresponding values
for CDTR, CFPN, and FRPM were set at B1 lg/ml (suscep-
tible), 2 lg/ml (intermediate), and C4 lg/ml (resistant).
Quinolone resistance was deﬁned as that equivalent to the
MIC of LVFX for E. coli, C4 lg/ml.
Assessment of the detection rate of E. coli
and S. saprophyticus by menopausal status
The detection rates of E. coli and S. saprophyticus were
statistically compared between premenopausal and post-
menopausal patients using the Fisher’s exact test. A P value
\ 0.05 indicates statistical signiﬁcance.
Results
Study population and patient characteristics
A total of 461 urine sampleswere registered from43 Japanese
hospitals during the study period, among which 364 samples
were included in the analysis and 97 samples were excluded.
The backgrounds of the patients are shown in Table 2. All the
patients with AUC were female. The mean age (± standard
deviation) was 49.1 ± 20.2 years, with elderly patients aged
C70 years accounting for 21.5 % of the urine samples. The
majority of the urine samples of samples were collected as
midstream urine (92.6 %). Among the women with AUC,
47.3 % were postmenopausal.
Causative bacteria
The causative bacteria are shown in Table 3. The number of
strains isolated as causative bacteria from 461 patients with
AUC was 387. Major causative bacteria included 301 E. coli
(77.8 %), 20 S. saprophyticus (5.2 %), 13 Klebsiella pneu-
moniae (3.4 %), 11 Enterococcus faecalis (2.8 %), and 8
Streptococcus agalactiae (2.1 %). Gram-negative and gram-
positive bacteria, respectively, accounted for 86.3 % (334
strains) and 13.4 % (52 strains) of all strains. The gram-
negative/gram-positive ratio of the isolates was 13:2.
A stratiﬁed analysis of the detection rate of pathogens by
menopausal status was performed. Among the women with
AUC whose causative bacterium was E. coli (median age, 53
years) orS. saprophyticus (median age, 24.5years), 49.2 %and
89.5 %, respectively,were premenopausal. The results showed
that infection with S. saprophyticus was signiﬁcantly more
common in premenopausal women (P = 0.00095) (Table 4).
Susceptibility proﬁle
The MIC distribution, i.e., MICs for 50 % and 90 % of
the organisms (MIC50 and MIC90 values, respectively),
J Infect Chemother (2013) 19:393–403 397
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is shown in Table 5. The susceptibility rate based on
the MIC breakpoints set by CLSI for each antimicrobial
agent are stratiﬁed by E. coli, ESBL-producing
E. coli, and S. saprophyticus in Figs. 1, 2, and 3,
respectively.
Antimicrobial susceptibility of Escherichia coli (301
strains)
The susceptibility rate of 301 E. coli strains isolated from
patients with AUC for oral cephalosporins was high
(92.0 % for CCL, 92.4 % for CPDX, 92.7 % for CFDN,
93.7 % for CDTR, and 94.0 % for CFPN), with the highest
susceptibility rate seen with CFPN (Fig. 1). The MIC90 of a
penicillin derivative (ABPC) in these E. coli strains was
C256 lg/ml, whereas the MIC90 of a penicillin derivative
in the presence of the b-lactamase inhibitors (CVA/AMPC)
decreased to 8 lg/ml (Table 5). The MIC90 of ﬁve oral
cephalosporins and one oral penem (FRPM) was 1–4 lg/ml
and, therefore, all of them were active against E. coli
(Table 5). The susceptibility rate for all ﬂuoroquinolones
was also high (87.7 % for LVFX, 98.0 % for STFX, 87.7 %
for CPFX, 91.5 % for TFLX), with the highest susceptibil-
ity rate seen with STFX (Fig. 1). The MIC90 of ﬁve ﬂuoro-
quinolones in these E. coli strains ranged from 1 to
C32 lg/ml, and the percentage of resistant strains was
12.3 %. Susceptibility to two aminoglycosides (GM and
AMK)was very high, with susceptibility rates of 93.7 % and
100 %, respectively. FOM was also very high with suscep-
tibility rates of 100 % (Fig. 1).
Fourteen ESBL-producing strains (14/301; 4.7 %) were
detected. In these strains, the MIC90 of ABPC and ﬁve oral
cephalosporins ranged from 64 to C256 lg/ml (Table 6),
and the susceptibility rate for all antimicrobials was
decreased except for CVA/AMPC, FRPM, aminoglyco-
sides, FOM, and ST. Remarkably, the ratio of resistant
strains for ABPC and oral cephalosporins was 100 %
(Fig. 2).
Table 2 Background of patients
n (%)
Gender
Female 461 100
Age (years)
16–19 14 3.0
20–29 91 19.7
30–39 69 15.0
40–49 50 10.8
50–59 70 15.2
60–69 68 14.8
70–79 64 13.9
80– 35 7.6
Collection of urine samples
via catheter 21 4.6
Midstream urine 427 92.6
Unknown 13 2.8
Menopausal status
Premenopausal 240 52.1
Postmenopausal 218 47.3
Unknown 3 0.7
Table 3 Causative organisms isolated from patients with acute
uncomplicated cystitis (AUC)
Organisms n (%)
Gram-negative bacteria 334 86.3
Escherichia coli 301 77.8
Klebsiella pneumoniae 13 3.4
Proteus mirabilis 6 1.6
Citrobacter koseri 4 1.0
Enterobacter aerogenes 3 0.8
Pseudomonas sp. 2 0.5
Citrobacter freundii 1 0.3
Proteus vulgaris 1 0.3
Proteus sp. 1 0.3
Morganella morganii 1 0.3
Pseudomonas aeruginosa 1 0.3
Gram-positive bacteria 52 13.4
Staphylococcus saprophyticus 20 5.2
Enterococcus faecalis 11 2.8
Streptococcus agalactiae 8 2.1
Staphylococcus sp. 7 1.8
Staphylococcus aureus 4 1.0
Streptococcus sp. 2 0.5
Candida sp. 1 0.3
Table 4 Stratiﬁed analysis on the detection rate of pathogens by
menopausal status
Bacterial strains
Escherichia coli Staphylococcus
saprophyticus
Age, years
Mean ± SD 50.7 ± 19.9 30.7 ± 12.3
Median 53 24.5
Range 16–89 18–56
Menopausal status, number (%)
Premenopausal 147 (49.2) NS 17 (89.5) *
Postmenopausal 152 (50.8) 2 (10.5)
NS indicates P value[0.05
* P = 0.00095
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Table 5 Distribution of minimal inhibitory concentration (MICs) of Escherichia coli (n = 301)
Antibacterial agent MIC (lg/ml)
B0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 C256 MIC50 MIC90
Ampicillin 9 104 94 10 4 3 5 72 4 C256
Clavulanic acid-amoxicillin 2 9 136 81 52 12 5 4 4 8
Cefaclor 16 107 113 32 6 3 2 3 4 1 14 1 4
Cefpodoxime 26 193 54 3 2 5 3 1 5 3 6 0.25 0.5
Cefdinir 24 167 73 11 4 1 6 3 7 5* 0.125 0.5
Cefditoren 10 156 100 12 4 4 1 2 4 8* 0.125 0.5
Cefcapene 3 34 179 61 6 3 2 3 8 1 1 0.25 0.5
Faropenem 57 198 43 3 0.5 1
Gentamicin 116 152 13 1 3 5 8 2 1 0.5 1
Amikacin 6 151 130 14 1 2
Ciproﬂoxacin 225 20 13 5 1 3 4 18 10 1 1 B0.06 8
Levoﬂoxacin 198 29 11 17 9 5 21 10 1 B0.06 8
Tosuﬂoxacin 227 23 10 2 1 1 2 1 34** B0.06 C32
Pruliﬂoxacin 234 25 3 1 4 4 23 5 1 1 B0.06 2
Sitaﬂoxacin 258 6 5 26 6 B0.06 1
Fosfomycin 2 60 152 55 18 3 5 3 3 0.5 2
Sulfamethoxazole/trimethoprim 173 71 9 8 2 1 1 36*** 0.063 C16
* C128 lg/ml, ** C32 lg/ml, *** C16 lg/ml
0% 20% 40% 60% 80% 100%
Sulfamethoxazole/Trimethoprim
fosfomycin
sitafloxacin
prulifloxacin
tosufloxacin 
levofloxacin
ciprofloxacin
amikacin
gentamicin
faropenem
cefcapene
cefditoren
cefdinir
cefpodoxime
cefaclor
clavulanic acid-amoxicillin
ampicillin
Susceptible
Intermediate
Resistant
Fig. 1 Antimicrobial
susceptibility of Escherichia
coli was categorized into three
classes: susceptible,
intermediate, or resistant,
according to the minimum
inhibitory concentration (MIC)
breakpoints recommended by
CLSI standards M100-S18.
Seventeen antimicrobial agents
were tested on 301 strains of
E. coli
0% 20% 40% 60% 80% 100%
Sulfamethoxazole/Trimethoprim
fosfomycin
sitafloxacin
prulifloxacin
tosufloxacin 
levofloxacin
ciprofloxacin
amikacin
gentamicin
faropenem
cefcapene
cefditoren
cefdinir
cefpodoxime
cefaclor
clavulanic acid-amoxicillin
ampicillin
Susceptible
Intermediate
Resistant
Fig. 2 Antimicrobial
susceptibility of extended-
spectrum b-lactamase (ESBL)-
producing Escherichia coli was
categorized into three classes:
susceptible, intermediate, or
resistant, according to the MIC
breakpoints recommended by
CLSI standards M100-S18.
Seventeen antimicrobial agents
were tested on 14 strains of
ESBL-producing E. coli
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Antimicrobial susceptibility of Staphylococcus
saprophyticus (20 strains)
The 20 S. saprophyticus strains isolated from patients with
AUC showed variable susceptibility to oral b-lactam anti-
biotics. The MIC90 of two penicillin derivatives (ABPC
and CVA/AMPC) was 0.5–2 lg/ml, and that of ﬁve oral
cephems and one oral penem (FRPM) was 0.5–4 lg/ml.
Therefore, all were active against S. saprophyticus, except
for two cephalosporins (CPDX and CFPM) (Table 7). The
MIC90 of ﬂuoroquinolones in S. saprophyticus ranged from
B0.06 to 0.5 lg/ml, and ﬂuoroquinolone-resistant strains
were not seen (Table 7). All the S. saprophyticus strains
were susceptible to two aminoglycosides (GM and AMK)
and two glycopeptides (VCM and TEIC) (Fig. 3). On the
other hand, the MIC50 and MIC90 of FOM were 64 and
C256 lg/ml, respectively.
Discussion
AUC accounts for the greatest number of UTIs, particularly
among young, sexually active, and postmenopausal
women. A previous study has reported that 50–60 % of
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Sulfamethoxazole/Trimethoprim
teicoplanin
vancomycin
fosfomycin
sitafloxacin
prulifloxacin
tosufloxacin 
levofloxacin
ciprofloxacin
amikacin
gentamicin
faropenem
cefcapene
cefditoren
cefdinir
cefpodoxime
cefaclor
clavulanic acid-amoxicillin
ampicillin
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Intermediate
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Fig. 3 Antimicrobial
susceptibility of Staphylococcus
saprophyticus was categorized
into three classes: susceptible,
intermediate, or resistant,
according to the MIC
breakpoints recommended by
CLSI standards M100-S18.
Nineteen antimicrobial agents
were tested on 20 strains of
S. saprophyticus
Table 6 Distribution of minimal inhibitory concentration (MICs) of extended-spectrum b-lactamase (ESBL)-producing Escherichia coli
(n = 14)
Antibacterial agent MIC (lg/ml)
B0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 C256 MIC50 MIC90
Ampicillin 14 C256 C256
Clavulanic acid-amoxicillin 6 6 2 8 16
Cefaclor 14 C256 C256
Cefpodoxime 1 5 2 6 128 C256
Cefdinir 3 6 5* 64 C128
Cefditoren 1 1 4 8* C128 C128
Cefcapene 1 3 8 1 1 32 64
Faropenem 6 7 1 1 1
Gentamicin 6 7 1 0.5 0.5
Amikacin 3 8 3 2 4
Ciproﬂoxacin 1 2 1 2 4 2 1 1 16 64
Levoﬂoxacin 2 2 1 6 2 1 8 16
Tosuﬂoxacin 1 2 1 10** C32 C32
Pruliﬂoxacin 3 1 1 7 1 1 4 16
Sitaﬂoxacin 3 1 2 6 2 1 2
Fosfomycin 2 8 2 1 1 0.5 2
Sulfamethoxazole/
trimethoprim
6 1 1 6 0.125 C16
* C128 lg/ml, ** C32 lg/ml
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women experience at least one UTI in their lifetime [12].
According to the guidelines for antimicrobial use published
by JAID and JSC in 2005, the standard antimicrobial reg-
imen for the treatment of AUC is 3 days of therapy with
ﬂuoroquinolones or 7 days with b-lactam antibiotics.
However, recent reports have indicated increased isolation
of ﬂuoroquinolone-resistant or ESBL-producing gram-
negative bacilli in patients with UTIs worldwide [4, 13–
15]. Striking evidence is seen in the increase of E. coli
strains resistant to ﬂuoroquinolones, which could reﬂect the
overuse of quinolones for treatment of community-
acquired UTIs. It has been suggested that quinolone
resistance is higher in developing countries, as opposed to
that in developed nations, because of the use of less active
quinolones, such as nalidixic acid, or the use of ineffective
doses, which result in selection of mutant isolates [16].
Under such circumstances, to use antimicrobial agents
appropriately, it is important to conﬁrm the susceptibility
proﬁle of causative bacteria and to select the correct agents.
Accordingly, we investigated the distribution of causative
bacteria and their susceptibility proﬁle to 19 antimicrobial
agents in patients with AUC diagnosed according to the
Japanese guidelines for clinical trials on genitourinary tract
infections [5].
The microbial etiology of uncomplicated UTIs has been
regarded as well established and reasonably consistent,
although with a noticeable increase in antimicrobial resis-
tance in recent years. E. coli remains the predominant
uropathogen isolated in acute uncomplicated UTIs, fol-
lowed by S. saprophyticus [17, 18]. E. coli comprised the
largest number (301 of 387; 77.8 %) of isolates in the
study. When we compare these data to mega-surveillance
data in other countries [13, 14, 19], the distribution of
causative bacteria for uncomplicated UTIs was similar to
that in published studies. On the other hand, the present
isolation rate of S. saprophyticus was slightly higher (20 of
387; 5.2 %) than that in recent worldwide studies [13, 14].
S. saprophyticus is second only to E. coli as the most
frequent causative organism of AUC in women. As
approximately one-half of the female patients with AUC
were premenopausal, a stratiﬁed analysis on the detection
rate of E. coli and S. saprophyticus by menopausal status
was performed. The results showed that the detection rate
of E. coli was 72.4 % in 240 premenopausal women (147/
203 strains) and 84.0 % in 218 postmenopausal women
(152/181 strains). No statistical difference was observed
(P = 0.0570). On the other hand, the results showed that
the detection rate of S. saprophyticus was 8.4 % in 240
Table 7 Distribution of minimal inhibitory concentration (MICs) of Staphylococcus saprophyticus (n = 20)
Antibacterial agent MIC(lg/ml)
B0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 C256 MIC50 MIC90
Ampicillin 14 3 1 1 1 0.25 2
Clavulanic acid-amoxicillin 8 10 1 1 0.5 0.5
Cefaclor 10 8 1 1 1 2
Cefpodoxime 7 11 1 1 4 4
Cefdinir 6 11 1 1 1* 0.25 0.5
Cefditoren 1 15 2 1 1 1 2
Cefcapene 2 8 8 2 1 2
Faropenem 7 11 2 0.5 0.5
Gentamicin 20 B0.06 B0.06
Amikacin 1 15 4 0.25 0.5
Ciproﬂoxacin 11 8 1 0.25 0.5
Levoﬂoxacin 3 17 1 1
Tosuﬂoxacin 10 9 1 B0.06 0.125
Pruliﬂoxacin 1 16 3 0.25 0.5
Sitaﬂoxacin 20 B0.06 B0.06
Fosfomycin 9 4 3 4 64 C256
Vancomycin 15 5 1 2
Teicoplanin 11 6 3 1 4
Sulfamethoxazole/
trimethoprim
6 13 1 0.063 0.063
* C128 lg/ml
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premenopausal women (17/203 strains) and 1.1 % in 218
postmenopausal women (2/181 strains), and a statistical
difference was observed (P = 0.00095). These results are
consistent with the previous report that the majority of
UTIs by S. saprophyticus occur in young sexually active
women [20]. Therefore, this study highlights two major
bacterial uropathogens: E. coli and S. saprophyticus.
In Japan, ﬂuoroquinolone-resistant E. coli has been
noted as a clinical problem. Because various bacteria can
cause UTIs, ﬂuoroquinolones may be appropriate for
empirical therapy because of their wide spectrum of
activity. However, it has also been reported that a major
risk factor for ﬂuoroquinolone-resistant E. coli is recent
(within 1 month) ﬂuoroquinolone use and recurrent UTIs
[4, 21]. In this study, the proportion of ﬂuoroquinolone-
resistant or intermediate E. coli isolated from AUC was
12.3 %, slightly higher than the rate of 8.2 % from our
recent study [4]. When STFX (98.0 %) was excluded, the
ﬂuoroquinolones susceptibility rates of E. coli isolated
from AUC ranged from 87.3 % to 87.7 %, slightly lower
than the rates of 92.0–94.0 % for oral cephalosporins.
STFX shows high activity against bacteria resistant to
existing ﬂuoroquinolones and has been available since
2008 [22]. On the other hand, the susceptibility rates of
E. coli were 99.0 % for FRPM and 100 % for FOM, so
both antimicrobials had rates similar to that of STFX. In
the guidelines for antimicrobial use published by JSC and
JAID, 3 days of therapy with ﬂuoroquinolones or 7 days
with b-lactam antibiotics is recommended for empirical
therapy of AUC, although these regimens should be
reevaluated in the next decade. Low-dose ﬂuoroquinolones
should no longer be used because of the potential for
emergence of resistance [23]. Thus, the results presented
herein suggest the appropriateness of such an empirical
treatment. Furthermore, STFX, oral cephalosporins,
FRPM, or FOM should be chosen when E. coli is the likely
cause.
Another problem is the emergence of multi-antibiotic-
resistant E. coli. Fluoroquinolone-resistant E. coli strains
isolated from patients with UTIs are frequently resistant to
other antimicrobials. Production of ESBL in E. coli largely
contributes to resistance to the third- and fourth-generation
cephalosporins. This study found 14 ESBL-producing
E. coli (4.7 %), which is about four times higher than that
of previous data in Japan, which showed only 4 ESBL-
producing E. coli (1.1 %) among the 351 strains isolated in
2003 [24]. Against these ESBLs, the rates of susceptibility
were 100 % to AMK and FOM, and 0 % to ABPC, CCL,
CPDX, CFDN, CDTR, and CFPN. Thus, the frequency of
ESBL-producing E. coli from AUC is increasing, although
as yet it is not very high. However, the use of many dif-
ferent classes of antibiotics in the same patient may cause
the mutants to be resistant to structurally and functionally
diverse antibiotics [25]. An important factor impacting the
high frequency of antimicrobial-resistant bacteria may be
the aberrant use of antibiotics. A urine culture and an
antimicrobial susceptibility test of the urine specimen seem
to be essential for diagnosing the disease, recommending
the use of appropriate antibiotics, and reducing the number
of antibiotic-resistant uropathogens.
S. saprophyticus is uniquely associated with uncompli-
cated UTI in humans. The prevalence of colonization of S.
saprophyticus of the urogenital tract among healthy women
was 6.9 %; the most common site of colonization was the
rectum (40 %) [26]. UTI caused by S. saprophyticus is
associated with recent sexual intercourse and occurs more
often during late summer and fall [27]. The microorgan-
isms colonize the human gastrointestinal tract, particularly
during the gastroenteritis season in the summer and fall,
which likely accounts for the observed seasonal variation
in the incidence of UTI caused by S. saprophyticus [20]. In
addition, signiﬁcantly more patients infected with S. sap-
rophyticus complained of dysuria, urinary frequency, and
back pain than did patients infected with E. coli [28].
S. saprophyticus strains studied here showed high suscep-
tibility to ﬂuoroquinolones and aminoglycoside antibiotics
compared to other b-lactams (Fig. 3), and marked resis-
tance to CPDX, CFPM, and FOM, with a resistance
ranging from 35 % to 65 % (Fig. 1). Other antibiotics
found to be effective against S. saprophyticus were van-
comycin and teicoplanin, as none of the strains showed
resistance to them. We suppose that ﬂuoroquinolones and
aminoglycoside antibiotics could be used to treat AUC in
young sexually active women from the results of this study.
However, recurrence of UTI caused by to S. saprophyticus
is common. In addition, single-dose therapy with ﬂuoro-
quinolones is less effective than a 3-day course [29].
Conclusions
AUC is of signiﬁcance in the community because of its
high prevalence. To use antimicrobial agents appropriately,
it is important to conﬁrm the susceptibility proﬁle of
causative bacteria before treatment. When empiric therapy
is required, careful consideration of patient characteristics
appears to be important for choosing the correct agents.
However, the increasing prevalence of UTIs and antibiotic-
resistant bacteria has made empiric antibiotic treatment
increasingly more difﬁcult. In the next decade, an
increasing number of isolates of ﬂuoroquinolone-resistant
pathogens, as well as ESBL-producing strains, could be a
serious clinical problem. It is important that physicians are
aware of regional resistance ratios before initiating empiric
antimicrobial therapy for the treatment of AUC. The data
obtained from this study provide essential information
402 J Infect Chemother (2013) 19:393–403
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about the trends of antimicrobial-resistant pathogens and
will help determine the optimal treatment for patients with
AUC. In addition, the data are retained for comparison with
the isolation of antibiotic-resistant organisms from periodic
future surveillance.
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